152 related articles for article (PubMed ID: 34620744)
1. Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
Yang Y; Xu H; Zhang L; Bai L; Zhu H; Li Q
Anticancer Drugs; 2022 Feb; 33(2):214-219. PubMed ID: 34620744
[TBL] [Abstract][Full Text] [Related]
2. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
Matsubara Y; Ando T; Hosokawa A; Mihara H; Takagi H; Nakata N; Yoshita H; Nanjo S; Kajiura S; Fujinami H; Sugiyama T
Intern Med; 2018 Mar; 57(5):671-675. PubMed ID: 29151523
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series.
Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Toru H; Suzuki S
J Obstet Gynaecol Res; 2023 Dec; 49(12):2868-2874. PubMed ID: 37658751
[TBL] [Abstract][Full Text] [Related]
5. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Tian Z; Dong S; Yang Y; Gao S; Yang Y; Yang J; Zhang P; Wang X; Yao W
BMC Cancer; 2022 Jan; 22(1):56. PubMed ID: 35022029
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
[TBL] [Abstract][Full Text] [Related]
9. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
10. Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.
Li B; Tao W; Shao-Hua Z; Ze-Rui Q; Fu-Quan J; Fan L; Ze-Fei J
Cancer Biol Ther; 2018 Apr; 19(4):292-295. PubMed ID: 29333945
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report.
Sawayama H; Komohara Y; Hirao H; Sakata K; Takata N; Yoshinaka I; Harada K; Baba H
Clin J Gastroenterol; 2020 Oct; 13(5):759-765. PubMed ID: 32592148
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib plus camrelizumab achieved long-term survival in a patient with metastatic esophageal neuroendocrine carcinoma.
Zhou L; Xu G; Chen T; Wang Q; Zhao J; Zhang T; Duan R; Xia Y
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1855. PubMed ID: 37381647
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
16. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
17. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
20. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
